CDC42 and breast carcinoma: Injection of RhoA or Cdc42 prevents breast cancer cells from mAb200 (Ras-GAP inhibitor)-induced apoptosis but no additional effects are seen upon Cdc42/RhoA co-injection, which demonstrates that the protective function of Cdc42 in breast cancer results from RhoA activation [137].